Sept. 12, 2006 — Some common painkillers are much less secure than others, two unused studies appear.

The two studies look at existing clinical trial data for the common kind of painkillers known as NSAIDs (nonsteroidal anti-inflammatory drugs), particularly the NSAIDs known as Cox-2 inhibitors.

The thinks about include to the shrewdness of the 2004 decision to evacuate the Cox-2 inhibitor Vioxx from market. It carries a surprisingly tall risk — not as it were for possibly lethal heart issues, but moreover for kidney trouble.

The modern data also raise alarming questions about the more seasoned NSAID, diclofenac, sold blandly and also under the brand names Voltaren and Cataflam.

On the other hand, the ponders show that low doses of the Cox-2 inhibitor Celebrex — beneath 200 milligrams per day — show up moderately more secure. They seem to suggest that the problems with Vioxx don’t naturally involve all other Cox-2 drugs.

Painkillers With Moo Heart Hazard

The safest painkiller in respects to heart risk in these ponders is naproxen, sold under the brand name Aleve and Naprosyn. Also clearly safe in respects to heart risk are ibuprofen (sold as Advil, Motrin, Nupren, and other brand names) and piroxicam (sold as Feldene).

Although caution is certainly warranted, the new findings appear no reason why clinical trials of modern Cox-2 drugs — to be called ArCoxia and Glory — should not proceed.

Since of their pertinence to buyers, the thinks about were released early by The Journal of the American Medical Affiliation. They will appear in the journal’s Oct. 4 issue.

In a piece going with the thinks about, FDA medicate security commentator David J. Graham, MD, MPH — composing for himself and not for the FDA — notes that safety issues with Vioxx were apparent long before the medicate was expelled from the market. But since the FDA had no authoritative verification of this risk, it did not ban the medicate.

Graham — as well as the authors of one of the papers, Harvard analysts Jingjing Zhang, MD, PhD, and colleagues — call for major changes in the way the FDA assesses medicate security.

“We clearly still have a lot to learn approximately the pharmacological impacts of Cox-2 inhibitors,” Zhang said, in a news discharge. “In the mean time, both physicians and patients ought to exercise careful thought before using NSAIDs and Cox-2 inhibitors.”